このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Attana マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Teodor Aastrup

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	11.9%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

CEO（最高経営責任者

Teodor Aastrup (54 yo)

less than a year

在職期間

Dr. Teodor Aastrup, Ph D., is a Co-Founder and Director of Attana AB and served as its Chief Scientific Officer since September 2023 until 2024 and served as its Chief Executive Officer since 2024. Dr. Aas...

Attana マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Director exercised options to buy kr102k worth of stock.

No independent directors

Attana Announces CEO Changes

No independent directors

No independent directors

Chairman of the Board recently bought kr90k worth of stock

Recent updates

Director exercised options to buy kr102k worth of stock.

First quarter 2024 earnings released

Full year 2023 earnings released: kr0.051 loss per share (vs kr0.07 loss in FY 2022)

New minor risk - Shareholder dilution

No independent directors

Attana Announces CEO Changes

The Swedish Knowledge-Foundation Grants SEK 12 Million to Project Concerning Individual Immunity Profiles for Diagnostics and Medical Development Based on Attana's QCM Technology

New major risk - Revenue size

Full year 2022 earnings released: kr0.07 loss per share (vs kr0.081 loss in FY 2021)

Attana AB Submits International Patent Application

Attana AB has completed a Follow-on Equity Offering in the amount of SEK 11.4 million.

Attana Submits New Patent Application Regarding Neutralizing Effect in Complex Samples

Third quarter 2022 earnings released

Price target increased to kr1.15

No independent directors

Price target decreased to kr1.05

No independent directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Attana Submits New Patent Application

Chairman of the Board recently bought kr90k worth of stock

Third quarter 2021 earnings: Revenues exceed analyst expectations

Second quarter 2021 earnings released

Attana Obtains CE-IVD Marking for Its First Products Within Clinical Diagnostics

First quarter 2021 earnings released: kr0.017 loss per share (vs kr0.017 loss in 1Q 2020)

Attana AB Announces Approval and Initiation of Clinical Phase I/II Study for the New COVID-19 Vaccine

Attana Collaborates with Linnaeus University Toaccelerate the Development of Unique Antibody Tests for COVID-19

New 90-day low: kr1.30

Attana Completes FDA Medical Device Class 1 Listing and Facility Registration

Attanas Record Publishes in IBI Shows Extraordinary Results

Attana Receives Contract Research Order from Global Pharma Company

Third quarter 2020 earnings released: kr0.013 loss per share

New 90-day low: kr1.46

Attana Submits A New Patent Application

First half earnings released

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04